InvestorsHub Logo
Followers 6
Posts 1257
Boards Moderated 0
Alias Born 06/14/2009

Re: None

Friday, 02/03/2023 4:01:18 AM

Friday, February 03, 2023 4:01:18 AM

Post# of 3683
Something else is brewing regarding Japan's Kyocera pulling out of Australia's Regeneus deal for stem cell therapy Progenza for osteoarthritis which ATHX seems to be in play ...

News of the deal falling apart is a particular blow to Regeneus, because it saw the deal as a validation of its technology, and it specifically chose the Japan market as its entry point because it believed it would quickly gain approval and be able to commercialize the product in other territories. Under the terms of the deal, Regeneus, of Sydney, was to receive $19 million in up-front and milestone payments, consisting of $9 million up front and $10 million in regulatory and development milestones. Regeneus would have also received double-digit royalties on sales and retained rights to negotiate licenses with other partners for additional indications inside and outside of Japan.

Check out Athersys' leadership page on the company's website which has been updated. The timing regarding of the announcement is positive. Dan has been AVOIDING any mention of a partnership until it is a done deal, something that could happen VERY soon. Get your ????? in order which they are inviting people to submit ??????????? .... GOOD LUCK LONGS